Michael Castagna
Amministratore Delegato presso MANNKIND CORPORATION
Patrimonio netto: 12 M $ in data 31/05/2024
Profilo
Michael E.
Castagna is currently the Chief Executive Officer & Director at MannKind Corp.
He is also a Director at Pet Partners.
Previously, he held positions as the Executive Director-Immunology Franchise at Bristol Myers Squibb Co. from 2010 to 2012, Director at Pharmasset, Inc. in 2005-2006, Vice President-Global Commercial at Amgen, Inc. from 2012 to 2016, and Vice President & Head-Biopharmaceuticals at Sandoz, Inc. from 2009 to 2010.
He also served as the VP & Head-North America Biopharmaceuticals at Novartis AG.
Dr. Castagna obtained a doctorate degree from Massachusetts College of Pharmacy & Health Science in 2014, an MBA from The Wharton School of the University of Pennsylvania in 2005, and an undergraduate degree from Philadelphia College of Pharmacy in 2000.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
MANNKIND CORPORATION
0.92% | 18/05/2024 | 2 511 230 ( 0.92% ) | 12 M $ | 31/05/2024 |
Posizioni attive di Michael Castagna
| Società | Posizione | Inizio |
|---|---|---|
| MANNKIND CORPORATION | Amministratore Delegato | 25/05/2017 |
| Pet Partners | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Michael Castagna
| Società | Posizione | Fine |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 14/03/2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2012 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/11/2010 |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Direttore/Membro del Consiglio | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formazione di Michael Castagna
| Philadelphia College of Pharmacy | Undergraduate Degree |
| Massachusetts College of Pharmacy & Health Science | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| MANNKIND CORPORATION | Health Technology |
| AMGEN INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Aziende private | 3 |
|---|---|
| Pet Partners | |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
- Borsa valori
- Insiders
- Michael Castagna
